Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia
Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved pharmacologic treatments. RJx-01 offers a multi-pathway approach targeting several drivers of muscle decline, including mitochondrial dysfunction, inflammation, fibrosis and neuromuscular impairment. Topline data expected by year-end 2026 represents a near-term clinical inflection point for Rejuvenate Biomed’s lead asset and further platform validation.
Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia
The randomized, Phase 2, double-blind, placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD
Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia
The Phase 2 double-blind placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD. Rejuvenate Biomed anticipates commencing patient enrollment first half 2025
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools
Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools
Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia.